CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 28 enrolled
Drug / intervention
BIBW 2992 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00708214
NCT00708214Phase 2Completed
CompareCT.gov

A Phase II Study of BIBW 2992 Administration in Patients With Hormone Refractory Metastatic Breast Cancer

Boehringer Ingelheim·interventional·Posted Jul 2, 2008·Updated Dec 30, 2013

In Brief

A Phase 2 clinical trial evaluating BIBW 2992 and Letrozole for Breast Neoplasms. Completed, enrolled 28 participants across 5 sites.

Detailed Summary

Progression-free rate after 16 weeks of BIBW 2992 administration in association with letrozole

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Neoplasms
CountriesFrance
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2, 2008
Enrollment StartJan 1, 2007
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 18 years ago

Interventions

BIBW 2992drug

BIBW 2992 at high and medium dosages

BIBW 2992drug

BIBW 2992 at high and medium dosages

Letrozoledrug

Letrozole at standard dosage

Letrozoledrug

Letrozole at standard dosage